353 related articles for article (PubMed ID: 11127943)
1. The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo.
Shi B; Yaremko B; Hajian G; Terracina G; Bishop WR; Liu M; Nielsen LL
Cancer Chemother Pharmacol; 2000; 46(5):387-93. PubMed ID: 11127943
[TBL] [Abstract][Full Text] [Related]
2. Combination therapy with the farnesyl protein transferase inhibitor SCH66336 and SCH58500 (p53 adenovirus) in preclinical cancer models.
Nielsen LL; Shi B; Hajian G; Yaremko B; Lipari P; Ferrari E; Gurnani M; Malkowski M; Chen J; Bishop WR; Liu M
Cancer Res; 1999 Dec; 59(23):5896-901. PubMed ID: 10606231
[TBL] [Abstract][Full Text] [Related]
3. Effects of insulin-like growth factor binding protein-3 and farnesyltransferase inhibitor SCH66336 on Akt expression and apoptosis in non-small-cell lung cancer cells.
Lee HY; Moon H; Chun KH; Chang YS; Hassan K; Ji L; Lotan R; Khuri FR; Hong WK
J Natl Cancer Inst; 2004 Oct; 96(20):1536-48. PubMed ID: 15494604
[TBL] [Abstract][Full Text] [Related]
4. Isotype-specific Ras.GTP-levels predict the efficacy of farnesyl transferase inhibitors against human astrocytomas regardless of Ras mutational status.
Feldkamp MM; Lau N; Roncari L; Guha A
Cancer Res; 2001 Jun; 61(11):4425-31. PubMed ID: 11389071
[TBL] [Abstract][Full Text] [Related]
5. Farnesyl transferase inhibitor SCH66336 is cytostatic, pro-apoptotic and enhances chemosensitivity to cisplatin in melanoma cells.
Smalley KS; Eisen TG
Int J Cancer; 2003 Jun; 105(2):165-75. PubMed ID: 12673674
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice.
Liu M; Bryant MS; Chen J; Lee S; Yaremko B; Lipari P; Malkowski M; Ferrari E; Nielsen L; Prioli N; Dell J; Sinha D; Syed J; Korfmacher WA; Nomeir AA; Lin CC; Wang L; Taveras AG; Doll RJ; Njoroge FG; Mallams AK; Remiszewski S; Catino JJ; Girijavallabhan VM; Bishop WR
Cancer Res; 1998 Nov; 58(21):4947-56. PubMed ID: 9810004
[TBL] [Abstract][Full Text] [Related]
7. The farnesyl protein transferase inhibitor SCH66336 is a potent inhibitor of MDR1 product P-glycoprotein.
Wang E; Casciano CN; Clement RP; Johnson WW
Cancer Res; 2001 Oct; 61(20):7525-9. PubMed ID: 11606389
[TBL] [Abstract][Full Text] [Related]
8. The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase.
Marcus AI; Zhou J; O'Brate A; Hamel E; Wong J; Nivens M; El-Naggar A; Yao TP; Khuri FR; Giannakakou P
Cancer Res; 2005 May; 65(9):3883-93. PubMed ID: 15867388
[TBL] [Abstract][Full Text] [Related]
9. The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity.
Basso AD; Mirza A; Liu G; Long BJ; Bishop WR; Kirschmeier P
J Biol Chem; 2005 Sep; 280(35):31101-8. PubMed ID: 16006564
[TBL] [Abstract][Full Text] [Related]
10. Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia.
Peters DG; Hoover RR; Gerlach MJ; Koh EY; Zhang H; Choe K; Kirschmeier P; Bishop WR; Daley GQ
Blood; 2001 Mar; 97(5):1404-12. PubMed ID: 11222387
[TBL] [Abstract][Full Text] [Related]
11. Derivation and initial characterization of a mouse mammary tumor cell line carrying the polyomavirus middle T antigen: utility in the development of novel cancer therapeutics.
Nielsen LL; Gurnani M; Shi B; Terracina G; Johnson RC; Carroll J; Mathis JM; Hajian G
Cancer Res; 2000 Dec; 60(24):7066-74. PubMed ID: 11156413
[TBL] [Abstract][Full Text] [Related]
12. Effects of SCH 59228, an orally bioavailable farnesyl protein transferase inhibitor, on the growth of oncogene-transformed fibroblasts and a human colon carcinoma xenograft in nude mice.
Liu M; Bryant MS; Chen J; Lee S; Yaremko B; Li Z; Dell J; Lipari P; Malkowski M; Prioli N; Rossman RR; Korfmacher WA; Nomeir AA; Lin CC; Mallams AK; Doll RJ; Catino JJ; Girijavallabhan VM; Kirschmeier P; Bishop WR
Cancer Chemother Pharmacol; 1999; 43(1):50-8. PubMed ID: 9923541
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of ER-51785, a new peptidomimetic inhibitor of farnesyl transferase: synergistic effect in combination with paclitaxel.
Nakamura K; Yamaguchi A; Namiki M; Ishihara H; Nagasu T; Kowalczyk JJ; Garcia AM; Lewis MD; Yoshimatsu K
Oncol Res; 2001; 12(11-12):477-84. PubMed ID: 11939411
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of cell growth in human glioblastoma cell lines by farnesyltransferase inhibitor SCH66336.
Glass TL; Liu TJ; Yung WK
Neuro Oncol; 2000 Jul; 2(3):151-8. PubMed ID: 11302335
[TBL] [Abstract][Full Text] [Related]
16. In vitro study of farnesyltransferase inhibitor SCH 66336, in combination with chemotherapy and radiation, in non-small cell lung cancer cell lines.
Loprevite M; Favoni RE; De Cupis A; Scolaro T; Semino C; Mazzanti P; Ardizzoni A
Oncol Rep; 2004 Feb; 11(2):407-14. PubMed ID: 14719076
[TBL] [Abstract][Full Text] [Related]
17. A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity.
Adjei AA; Erlichman C; Davis JN; Cutler DL; Sloan JA; Marks RS; Hanson LJ; Svingen PA; Atherton P; Bishop WR; Kirschmeier P; Kaufmann SH
Cancer Res; 2000 Apr; 60(7):1871-7. PubMed ID: 10766174
[TBL] [Abstract][Full Text] [Related]
18. Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines.
Adjei AA; Davis JN; Bruzek LM; Erlichman C; Kaufmann SH
Clin Cancer Res; 2001 May; 7(5):1438-45. PubMed ID: 11350915
[TBL] [Abstract][Full Text] [Related]
19. Anti-tumour activity of a panel of taxanes toward a cellular model of human cervical cancer.
Gallo D; Ferlini C; Distefano M; Cantelmo F; Gaggini C; Fattorossi A; Riva A; Bombardelli E; Proietti E; Mancuso S; Scambia G
Cancer Chemother Pharmacol; 2000; 45(2):127-32. PubMed ID: 10663627
[TBL] [Abstract][Full Text] [Related]
20. Comparative antitumor efficacy of docetaxel and paclitaxel in nude mice bearing human tumor xenografts that overexpress the multidrug resistance protein (MRP).
Vanhoefer U; Cao S; Harstrick A; Seeber S; Rustum YM
Ann Oncol; 1997 Dec; 8(12):1221-8. PubMed ID: 9496387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
